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SUMMARY 
RNA polymerase II (RNAPII) transcription is governed by the Pre-Initiation Complex (PIC), which 
contains TFIIA, TFIIB, TFIID, TFIIE, TFIIF, TFIIH, RNAPII, and Mediator.  After initiation, RNAPII 
enzymes pause after transcribing less than 100 bases; precisely how RNAPII pausing is enforced 
and regulated remains unclear. To address specific mechanistic questions, we reconstituted human 
RNAPII promoter-proximal pausing in vitro, entirely with purified factors (no extracts).  As expected, 
NELF and DSIF increased pausing, and P-TEFb promoted pause release.  Unexpectedly, the PIC 
alone was sufficient to reconstitute pausing, suggesting RNAPII pausing is an inherent PIC function.  
In agreement, pausing was lost upon replacement of the TFIID complex with TATA-binding protein 
(TBP), and PRO-seq experiments revealed widespread disruption of RNAPII pausing upon acute 
depletion (t=60 min) of TFIID subunits in human or Drosophila cells.  These results establish a TFIID 
requirement for RNAPII pausing and suggest pause regulatory factors may function directly or 
indirectly through TFIID. 
 
INTRODUCTION 
RNA polymerase II (RNAPII) transcribes all protein-coding and many non-coding RNAs in the human 
genome.  RNAPII transcription initiation occurs within the Pre-Initiation Complex (PIC), which 
contains TFIIA, TFIIB, TFIID, TFIIE, TFIIF, TFIIH, RNAPII, and Mediator.  After initiation, RNAPII 
enzymes typically pause after transcribing 20-80 bases (Kwak and Lis, 2013), and paused 
polymerases represent a common regulatory intermediate (Core et al., 2008; Jonkers et al., 2014; 
Muse et al., 2007; Zeitlinger et al., 2007).  Accordingly, paused RNAPII has been implicated in 
enhancer function (Ghavi-Helm et al., 2014; Henriques et al., 2018), development and homeostasis 
(Adelman et al., 2009; Lagha et al., 2013) and diseases ranging from cancer (Lin et al., 2010; Miller et 
al., 2017) to viral pathogenesis (Wei et al., 1998; Yamaguchi et al., 2001). Precisely how RNAPII 
promoter-proximal pausing is enforced and regulated remains unclear; however, protein complexes 
such as NELF and DSIF increase pausing whereas the activity of CDK9 (P-TEFb complex) correlates 
with pause release (Kwak and Lis, 2013).   
Although much has been learned about RNAPII promoter-proximal pausing and its regulation, 
the underlying molecular mechanisms remain enigmatic. One reason for this is the complexity of the 
human RNAPII transcription machinery, which includes the ~4.0 MDa PIC and many additional 
regulatory factors. Another underlying reason is that much current understanding derives from cell-
based assays, which are indispensable but cannot reliably address mechanistic questions.  For 
instance, factor knockdowns or knockouts cause unintended secondary effects and the factors and 
biochemicals present at each gene in a population of cells cannot possibly be defined.  In vitro assays 
can overcome such limitations, but these have typically involved nuclear extracts, which contain a 
similarly undefined mix of proteins, nucleic acids, and biochemicals.  To circumvent these issues, we 
sought to reconstitute RNAPII promoter-proximal pausing entirely from purified human factors (no 
extracts).  Success with this task enabled us to address some basic mechanistic questions and opens 
the door for future studies to better define the contribution of specific factors in RNAPII promoter-
proximal pause regulation. 
 
RESULTS 
Biochemical reconstitution reveals human PIC is sufficient to establish RNAPII pausing  
Past results in Drosophila and mammalian cells and extracts implicated the NELF, DSIF, and P-TEFb 
complexes as regulators of RNAPII pausing (Core et al., 2012; Li et al., 2013; Marshall and Price, 
1992).  We purified these factors in addition to the PIC factors TFIIA, TFIIB, TFIID, TFIIE, TFIIF, 
TFIIH, Mediator, and RNAPII (Figure S1).  Experiments were completed with the native human 
HSP70 promoter (HSPA1B gene), because others have shown that it is a quintessential model for 
promoter-proximal RNAPII pausing (Core et al., 2012).  Because chromatin per se does not appear to 
be an essential regulator of RNAPII pausing in Drosophila or mammalian cells (Kwak et al., 2013; Lai 
and Pugh, 2017; Li et al., 2013), the in vitro transcription assays were completed on naked DNA 
templates (also see below). 
Using purified PIC factors, primer extension assays established that transcription initiation 
occurred at the annotated HSPA1B start site in vitro (Figure S2A), as expected.  An overview of the 
transcription assay is shown in Figure 1A, which was based in part upon in vitro pausing assays with 
nuclear extracts (Marshall and Price, 1992; Qiu and Gilmour, 2017; Renner et al., 2001).  Following 
PIC assembly, transcription was initiated by adding ATP, GTP, and UTP at physiologically relevant 
concentrations, with a low concentration of CTP, primarily 32P-CTP. After one minute, reactions were 
chased with a physiologically relevant concentration of cold CTP and transcription was allowed to 
proceed for an additional nine minutes.  These “pulse-chase” assays allow better detection of short 
(potentially paused) transcripts, which otherwise would be drowned out by elongated transcripts that 
invariably possess more incorporated 32P-C bases.  By directly labeling all transcripts with 32P-CTP, 
the method is highly sensitive and allowed detection of transcripts of varied lengths; furthermore, the 
32P-CTP pulse-chase protocol ensured that 32P-labeled transcripts resulted almost exclusively from 
single-round transcription (see Methods).  Control experiments confirmed that transcripts detected 
were driven by the HSP70 promoter (e.g. not any contaminating nucleic acid) and that transcription 
was dependent on added PIC factors, as expected (Figure S2B). 
A variety of methods have established that RNAPII pauses after transcribing 20-80 bases in 
Drosophila and mammalian cells (Jonkers et al., 2014; Kwak et al., 2013; Lai and Pugh, 2017; Lee et 
al., 2008; Li et al., 2013; Muse et al., 2007; Nechaev et al., 2010; Zeitlinger et al., 2007). The 
HSPA1B promoter sequence used in our assays extended 216 base pairs beyond the transcription 
start site (TSS); thus, elongated transcripts would migrate on a sequencing gel between 100 and 216 
nucleotides (nt) and paused transcripts would be observed between 20 and 80 nt.  
Prior to testing DSIF/NELF and P-TEFb, we completed experiments with the PIC alone.  As 
expected, elongated transcripts were prevalent; however, we observed short transcripts, between 20 
and 80 nt, consistent with promoter-proximal RNAPII pausing (Figure 1B, lane 1). Potentially, these 
short transcripts could reflect premature termination. However, time course experiments showed that 
the shorter transcripts build up and then release over time (Figure 1C). In fact, the increase in 
elongated products between 5 to 10 minutes was equal to the loss of pause signal between 5 to 10 
minutes, suggesting a transient pause followed by release into elongation (see Discussion). 
Addition of NELF/DSIF to the reconstituted transcription system increased the levels of the 
short transcripts (20-80 nt) while decreasing the elongated products (Figure 1B, lane 2); these data 
were consistent with established roles for NELF/DSIF in RNAPII pausing (Kwak and Lis, 2013) and 
further suggested that the short transcripts represented promoter-proximal paused products. Addition 
of P-TEFb to reactions containing NELF/DSIF largely reversed the promoter-proximal pausing 
induced by NELF/DSIF (Figure 1B, lane 3); thus, P-TEFb appeared to increase RNAPII pause 
release in vitro, also consistent with current models (Kwak and Lis, 2013). A Pause Index (PI) was 
calculated and averaged across replicate experiments (n=8; Figure 1D), which showed that 
NELF/DSIF increased PI whereas P-TEFb decreased PI, as expected.  
 
RNAPII promoter-proximal pausing requires TFIID 
Because we were able to recapitulate pause enhancement with NELF/DSIF and pause release with 
P-TEFb at the native human HSPA1B promoter, this in vitro system appeared to reliably reconstitute 
basic mechanistic aspects of RNAPII promoter-proximal pausing. Whereas many potential questions 
could be addressed with this system, we focused on the unexpected result that promoter-proximal 
pausing was recapitulated with the PIC alone. We next tested whether RNAPII pausing would be 
dependent on a specific PIC factor. Although some factors could not be reliably evaluated given their 
requirement for transcription in this assay, removal of TFIIA, TFIIH, HSF1, or Mediator still supported 
transcription in vitro, although at reduced levels. These experiments showed little change in PI, 
suggesting that these factors were not required for RNAPII pausing in this assay (Figure S2C).  
We also addressed a potential dependence on the large, multi-subunit TFIID complex. 
Whereas RNAPII transcription was not supported by removal of TFIID, TBP can substitute for TFIID 
in vitro, provided that the DNA templates are not assembled into chromatin (Naar et al., 1998). 
Strikingly, we observed that when PICs were assembled with TBP instead of TFIID, transcription still 
occurred but promoter-proximal RNAPII pausing was lost (Figure 2A).  These data implicated TFIID 
as a key PIC factor that enabled RNAPII promoter-proximal pausing. To test further, we replaced 
endogenous purified human TFIID with a complete TFIID complex generated by recombinant 
expression (Figure 2B).  As shown in Figure 2C, the recombinant human TFIID complex performed 
similarly to endogenous TFIID, confirming that TFIID was required for RNAPII promoter-proximal 
pausing in vitro.  
Having established a TFIID dependence for RNAPII pausing, we sought to determine whether 
this activity could be attributed to any specific TFIID subunits. Human TFIID is approximately 1.4 MDa 
in size and contains TBP plus 13 different TBP-associated factors (TAFs), which are present in one or 
two copies each. The structures of human TFIID bound to promoter DNA reveal that lobe C—
containing TAF1, TAF2, and TAF7—binds downstream DNA (Louder et al., 2016; Patel et al., 2018). 
In particular, TAF1/2 interact with the Downstream Promoter Element (DPE) and the Motif Ten 
Element (MTE). At the HSPA1B promoter, these elements reside at template position +18 to +33 
relative to the transcription start site (TSS; Figure S1) (Vo Ngoc et al., 2017). Because the DPE and 
MTE encompass part of the RNAPII pause region, we hypothesized that lobe C subunits might be 
important in regulation of RNAPII promoter-proximal pausing. To test this hypothesis, we expressed 
and purified an “S-TAF” TFIID complex that contained only a subset of TAFs (Figure S2D).  The S-
TAF complex contains TBP as well as lobe C subunits TAF1 and TAF7.  As shown in Figure S2D, 
the S-TAF complex was able to support pausing, implying a role for TFIID lobe C for this function.  
 
Rapid depletion of TFIID lobe C subunits increases RNAPII pause release in human cells 
To further test the hypothesis that TFIID enables RNAPII promoter-proximal pausing, we turned to 
cell-based assays. To circumvent confounding issues with prolonged knockdown of essential TFIID 
subunits, we utilized the Trim-Away method (Clift et al., 2017), which enabled rapid (t=60 min) TAF 
subunit depletion (Figure 3A, B; Figure S3). (Numerous antibodies to various TAF subunits were 
tested prior to identification of a TAF1 antibody that reliably immunoprecipitated TFIID from extracts 
and depleted TAF1 using the Trim-Away protocol.)  With this approach, the effect of TFIID could be 
evaluated with minimal compensatory or cytotoxic consequences.  Indicative of a direct TAF1-TAF2 
interaction in lobe C, Trim-Away experiments targeting TAF1 also depleted TAF2 (TAF7 was not 
probed due to lack of reliable antibodies), and other TFIID subunits were depleted to varying degrees, 
except for TBP (Figure 3B & Figure S3). Because Trim-Away works through lysine modification by 
an E3 ubiquitin ligase, the enhanced TAF2 depletion vs. TAF1 may result from its disordered C-
terminus, which contains 14 lysines in a 30-residue stretch. 
Following acute TAF depletion using Trim-Away, we isolated nuclei and performed replicate 
PRO-seq experiments (TAF1/2 knockdown vs. controls).  The data showed good correlation between 
replicates (Figure S4A, B) and normalization tests (see Methods) confirmed that rapid TAF1/2 
knockdown did not dramatically shift overall transcription levels vs. controls (Figure 3C).  An 
expectation based upon our in vitro results (Figure 2A, C) and cryo-EM structural data (Louder et al., 
2016; Patel et al., 2018) was that TFIID might serve as a “brake” for promoter-associated RNAPII 
complexes and that removal of this brake would enhance pause release.  This expectation was 
confirmed by the PRO-seq data, which showed an overall increase in transcription, genome-wide 
(Figure S4C-E), except at non-annotated eRNAs (see below).  A representative protein-coding gene 
example is shown in Figure 3D, and genome-wide trends are shown as MA plots in Figure 3E, F.   
As might be expected from rapid depletion of TFIID lobe C subunits, the PRO-seq data 
showed transcriptional changes at thousands of gene 5’-ends.  In cells, increased pause release can 
also promote re-initiation by additional RNAPII enzymes (Gressel et al., 2017; Shao and Zeitlinger, 
2017).  In agreement, we observed increased 5’-end reads at thousands of genes (Figure 3F), and 
the reads extended beyond promoter-proximal pause regions (Figure 4A, inset), suggesting a defect 
in pause enforcement.  Unexpectedly, however, transcription sharply declined at approximately +300 
downstream of the TSS, as shown at JUN and HSPA1B (Figure 3D & Figure 4A, inset) and in a 
metagene plot representing all genes (Figure 4A & Figure S5).  We note that the sharp decline in 
reads beyond the promoter-proximal pause site superficially resembles RNAPII pausing; however, 
comparisons with PRO-seq data from flavopiridol-treated cells (a positive control for RNAPII pausing) 
showed stark differences and confirmed that pausing was not increased in TAF1/2-depleted cells 
(Figure S6).  The sharp decline in transcription at around +300 in TAF1/2-depleted cells explains the 
reduced increase in gene body reads (Figure 3E) compared with 5’-end reads (Figure 3F) and 
suggests the presence of a distinct factor(s) that functions at this later, post-pause release stage (see 
Discussion).  In contrast to annotated genes, transcription of non-annotated eRNAs declined overall 
in TAF1/2-depleted cells (Figure 4B), suggesting alternate regulatory mechanisms at these loci. As 
expected, a significant decrease in the TAF1 motif was observed in the Trim-Away depleted cells 
(Figure S6D). 
 
TFIID function in RNAPII promoter-proximal pausing is conserved in Drosophila 
Taf1 knockdown in Drosophila S2 cells has minimal impact on other TFIID subunits (Pennington et 
al., 2013; Wright et al., 2006), and promoter-proximal pausing is widespread in Drosophila (Muse et 
al., 2007; Nechaev et al., 2010; Zeitlinger et al., 2007).  To further test the impact of TAF1 (a TFIID 
lobe C subunit) on RNAPII pausing, Taf1 was knocked down in S2 cells and PRO-seq experiments 
were completed in triplicate (Figure 4C & Figure S7A). Consistent with TAF1/2-depleted human 
cells, Taf1 knockdown in Drosophila S2 cells showed a similar promoter-proximal increase in 
transcription, genome-wide (Figure 4C), suggesting increased pause release and increased re-
initiation with Taf1 knockdown (Figure S7B).  These data suggest a conserved role for TFIID in the 
regulation of RNAPII promoter-proximal pausing.  
 
DISCUSSION 
Structural data indicate that TFIID lobe C subunits TAF1 and TAF2 bind promoter DNA downstream 
from the TSS (Louder et al., 2016; Patel et al., 2018). Past studies revealed that insertion of 10 bp 
DNA at the +15 site relative to the TSS disrupted RNAPII pausing at the HSP70 gene in Drosophila 
S2 cells (Kwak et al., 2013).  This led to a “complex interaction” model for pausing, in which a 
promoter-bound factor(s) establishes an interaction (directly or indirectly) with the paused RNAPII 
complex.  In agreement with this model, we observe a TFIID requirement for RNAPII promoter-
proximal pausing in vitro, which is further supported by PRO-seq data in TAF-depleted human and 
Drosophila S2 cells. Additional evidence for TFIID-dependent regulation of RNAPII pausing derives 
from correlations among paused genes and DNA sequence elements bound by TFIID (Hendrix et al., 
2008; Lee et al., 2008; Li et al., 2013; Shao et al., 2019).  Defects in TFIID function are linked to 
numerous diseases, including cancer (Xu et al., 2018) and neurodegenerative disorders (Aneichyk et 
al., 2018).  Its requirement for RNAPII promoter-proximal pause regulation may underlie these and 
other biological functions. 
Biochemical reconstitution of RNAPII promoter-proximal pausing provides a level of 
mechanistic control that is simply not possible with cell-based assays; consequently, we were able to 
discover that RNAPII pausing is an inherent property of the human PIC and that TFIID is a key PIC 
factor that establishes pausing (Figure 2, Figure 4D).  Our results also reveal NELF, DSIF, and P-
TEFb as auxiliary factors that, although not required for pausing, enable robust regulation of this 
common transcriptional intermediate state.  Time-course experiments indicated that polymerases in 
the paused region remained active and generated elongated transcripts over time (Figure 1C).  
Experiments with P-TEFb showed enhanced release of paused intermediates, providing further 
evidence that polymerases in the paused region were active and competent for elongation (Figure 
1B, D).  However, some transcripts remained in the pause region after the 10-minute reactions, even 
with added P-TEFb.  This result is also consistent with current models that invoke alternative 
outcomes for promoter-proximal paused RNAPII, including premature termination (Erickson et al., 
2018; Krebs et al., 2017), arrest (Adelman et al., 2005), or a more stable paused intermediate (Chen 
et al., 2015; Henriques et al., 2013).  Addressing the mechanisms and factors that regulate these 
distinct outcomes could be explored in future studies.   
Despite its advantages, the reconstituted in vitro transcription assay does not match the 
complexity of regulatory inputs that converge upon active promoters in a living cell.  To test the TFIID 
requirement for promoter-proximal pausing in cells, we were able to rapidly deplete TFIID lobe C 
subunits TAF1 and TAF2 using Trim-Away (Clift et al., 2017), and genome-wide changes in nascent 
transcription were assessed with PRO-seq (Kwak et al., 2013).  Consistent with the in vitro data, 
global transcription increased at protein-coding genes upon TAF1/2 knockdown, with evidence for 
enhanced pause release (Figure 3D-F).  PRO-seq reads increased at 5’-ends and downstream of 
promoter-proximal pause sites at thousands of genes in TAF1/2 depleted cells.  These data are 
consistent with increased pause release and increased re-initiation (Figure 4D), two processes that 
are coupled in metazoan cells (Gressel et al., 2017; Shao and Zeitlinger, 2017).  Unexpectedly, 
however, increased pause release did not yield similar genome-wide increases in gene body reads.  
Instead, the PRO-seq data revealed a sharp reduction in reads downstream of promoter-proximal 
pause sites, at around +300 from the TSS in both human and Drosophila cells.  These results 
implicate additional regulatory mechanisms, downstream of the pause site, that may terminate or 
arrest RNAPII.  Although future studies are needed to identify the factors involved, we note that the 
Integrator complex was recently shown to cleave nascent transcripts downstream of pause sites at 
hundreds of genes in Drosophila cells (Tatomer et al., 2019).  Because promoter-proximal pausing 
helps ensure proper capping of transcripts at their 5’-ends (Rasmussen and Lis, 1993; Tome et al., 
2018), downstream regulatory mechanisms may become important when RNAPII promoter-proximal 
pausing is disrupted. 
A TFIID requirement for RNAPII promoter-proximal pausing implies that other pause regulatory 
factors may function directly or indirectly through TFIID.  Although additional mechanistic aspects 
remain to be addressed, it is notable that pause regulatory factors, including P-TEFb and MYC, 
interact (directly or indirectly) with TFIID (Gegonne et al., 2008; Wei et al., 2019; Yadav et al., 2019); 
moreover, TFIID is conformationally flexible (Cianfrocco et al., 2013) and likely undergoes structural 
reorganization during RNAPII transcription initiation and pause release (Yakovchuk et al., 2010; 
Zhang et al., 2015).  Such structural transitions may contribute to TFIID-dependent regulation of 
RNAPII pausing.  Whereas nucleosomes likely affect promoter-proximal pausing, they are not 
required, based upon our results and based upon data in Drosophila and mammalian systems 
(Benjamin and Gilmour, 1998; Kwak et al., 2013; Lai and Pugh, 2017; Li et al., 2013). TFIID 
possesses multiple domains that bind chromatin marks associated with transcriptionally active loci, 
including H3K4me3 (Jacobson et al., 2000; Vermeulen et al., 2007), which suggests TFIID function is 
regulated in part through epigenetic mechanisms.  Future studies should help establish whether 
specific chromatin marks contribute to TFIID-dependent regulation of RNAPII pausing, potentially by 
affecting TFIID promoter occupancy or by impacting TFIID structure and function. 
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Figure 1. Biochemical reconstitution of promoter-proximal RNAPII pausing with purified 
human factors. (A) Overview of in vitro transcription assay. (B)  Representative data from in vitro 
transcription reactions with the complete PIC (lane 1) or supplemented with NELF/DSIF (lane 2) and 
P-TEFb (lane 3).  At left are approximate lengths of the RNA transcripts. Note increased transcripts in 
paused region and reduced transcripts in elongation region upon addition of NELF and DSIF (lane 1 
vs. lane 2); addition of P-TEFb reverses this trend (lane 2 vs. lane 3). (C) A time course showing 
maximum paused transcripts at 5 minutes and maximum elongated transcripts at 10 minutes; the 
elongated transcripts increased in equal proportion to the decrease in paused transcripts (5 min vs. 
10 min), indicating that paused complexes can ultimately generate elongated products. (D) 
Calculation of an in vitro pause index (PI) at the HSP70 promoter, using paused and elongated 
regions defined in B. A NELF/DSIF outlier (PI=18) is not shown. Across replicate experiments (n=8) 
PI almost exclusively increased with NELF/DSIF and decreased with added P-TEFb.  The spread in 
the data is consistent with replicate-to-replicate PI variability observed in human cells (see Methods). 
Bars represent mean ± standard error. See also Figure S2E. 
 
Figure 2. TFIID is required to establish RNAPII promoter-proximal pausing in vitro. (A) 
Reconstituted transcription reactions with PICs containing TFIID or TBP (i.e. reactions contain TFIIA, 
IIB, IIE, IIF, IIH, Mediator, and RNAPII, plus either TFIID or TBP).  PICs with TBP still support 
transcription, but paused products were not observed (data from same gel).  Reduced [ATP] was 
used in these experiments compared to Figure 1, causing an upstream shift in pausing, similar to 
results seen in Drosophila (Li et al., 2013).  (B) Coomassie-stained gel of the complete human TFIID 
complex, generated by recombinant expression (Fitzgerald et al., 2006); *core TBP (residues 155-
335). (C) As with endogenously purified human TFIID, PICs with recombinant TFIID support 
transcription and RNAPII promoter-proximal pausing. Relative to A, increased [ATP] caused a 
downstream shift in paused products.   
 
Figure 3.  PRO-seq data suggest increased pause release upon TAF1/2 knockdown in human 
cells. (A) Workflow for TRIM-Away (Clift et al., 2017) and PRO-seq (Kwak et al., 2013). (B) 
Representative western blots and quantitation (at right) for TFIID subunits.  Bar plots represent mean 
and standard error, with actin as a loading control. (C) Normalization of PRO-seq data based upon 3’-
end reads of long genes (Mahat et al., 2016)(see Methods) or based upon total run-on signal 
comparing control vs. TAF1/2-knockdown samples (inset; bar = S.E.M).  (D) Genome browser view of 
PRO-seq reads at JUN locus (control vs. TAF1/2-depleted), which reflects genome-wide trends 
shown in MA plots for gene bodies (+500 to –500 from TES; E) and gene 5’-ends (–500 to +500; F). 
 
Figure 4.  Depletion of TFIID lobe C subunits increases pause release; TFIID function is 
conserved in Drosophila cells. (A) Metagene plot (all genes, n = 18687) of promoter-proximal 
region that shows increased 5’-end reads in TAF1/2 knockdown cells, which extend beyond the 
pause site.  These data are consistent with increases in pause release and re-initiation, which are 
coupled events in metazoan cells (Gressel et al., 2017; Shao and Zeitlinger, 2017).  A sharp 
reduction in reads typically occurs around +300 from the TSS (e.g. HSPA1B locus, inset; vertical 
dashed line +60 from TSS) which suggests downstream auxiliary factors that terminate or arrest 
RNAPII (see Discussion). (B) Metagene plot and MA plot (inset) of non-annotated regions, showing 
that eRNA transcription is reduced in TAF1/2 knockdown cells. (C) Metagene plot of expressed genes 
(n = 10995) in Drosophila, comparing control vs. Taf1 knockdown S2 cells.  As in TAF1/2 knockdown 
HCT116 cells, transcription increased at gene 5’-ends. Inset: Representative western blots showing 
Taf1 knockdown in S2 cells. Taf1 knockdown was determined to be 88% (± 6.7%) from 3 biological 
replicates.  (D) Model. TFIID is required to establish RNAPII promoter-proximal pausing. Disruption of 
TFIID lobe C correlates with increased RNAPII pause release, which enables other RNAPII 























KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
TAF1 Santa Cruz 
Biotechnology 
Cat#sc-735 X; RRID: 
AB_671202  
TAF2 abcam Cat#ab103468; RRID: 
AB_10716140 
TAF4 Millipore Sigma Cat#07-1803; RRID: 
10846677 
 
TAF8 abcam Cat#ab204894  








Histone H3 A. Shilatifard (Ebmeier 
et al., 2017). 
N/A 
TAF1 C413 for Trim-Away Recombinant Antibody 
Network 
Anti-TAF1-RAB-C413 
30H9 (Drosophila Taf1) Weinzierl et al., 1993 N/A 
3E12 (Drosophila Taf4) Marr et al., 2006 N/A 
Chemicals, Peptides, and Recombinant Proteins 
DTT Sigma-Aldrich cat#D0632 
Benzamidine Sigma-Aldrich cat#B6506-100G 
Sodium Metabisulfite Sigma-Aldrich cat#255556-100G 
Phenylmethylsulfonyl Fluoride American Bioanalytical cat#AB01620 
TRIzol™ Reagent Invitrogen cat#15596018 
TRIzol™ LS Reagent Invitrogen cat#10296028 
T4 Polynucleotide Kinase NEB cat#M0201S 
RNA 5' Pyrophosphohydrolase (RppH) NEB cat#M0356S 
ThermoPol® Reaction Buffer Pack NEB cat#B9004S 
T4 RNA Ligase 1 (ssRNA Ligase) NEB cat#M0204S 
SuperScript™ III Reverse Transcriptase Invitrogen cat#18080044 
Phusion® High-Fidelity DNA Polymerase NEB cat#M0530L 
SUPERase-In Invitrogen cat#AM2694 
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Lead contact and materials availability 
Requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, 
Dylan Taatjes (taatjes@colorado.edu). 
 
All reagents generated in this study are available from the Lead Contact without restriction or with a 
Materials Transfer Agreement. 
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
Drosophila cell culture. D. melanogaster Schneider line 2 (S2) cells were maintained at 25°C in 
Schneider‘s medium containing 10% (vol/vol) Fetalplex (Gemini), 100 units/mL penicillin, and 0.1 
mg/mL streptomycin.  
 
HCT116 cell culture. HCT116 cells were grown in McCoy's media (Gibco, 16600082) with Gibco 
100x Antibiotic-Antimycotic (Fisher Sci, 15240062) penicillin-streptomycin and 10% fetal bovine 
serum (FBS) supplementation. 
 
METHOD DETAILS 
HSPA1B promoter DNA template.  The native human HSPA1B promoter was amplified from 
genomic DNA (HeLa) by PCR (forward primer: CTCCTT CCCATT AAGACG GAAAAA ACATCC 
GGGAGA GCCGGT CCG; reverse primer: ACCTTG CCGTGT TGGAAC ACCCCC ACGCAG 
GAGTAG GTGGTG CCCAGGTC) and cloned into a pCR-Blunt-TOPO plasmid. The HSPA1B 
promoter corresponding to -500 to +216 base pairs relative to the transcription start site was amplified 
off this plasmid using Phusion polymerase (Thermo-Fisher #F530S). The resulting PCR product was 
then purified using the E.Z.N.A. Gel Extraction kit (Omega BioTek #D2500). The DNA was then 
ethanol precipitated, washed, resuspended to 100 nM in milliQ water, and stored frozen in single-use 
aliquots. 
 
Reconstituted in vitro transcription. The HSPA1B promoter template (5nM in 10 µL) was incubated 
with 400 nM HSF1 in template mix buffer (20 mM HEPES pH 7.6, 1 mM DTT, 8 mM MgCl2) at 30ºC 
for 20 minutes. Then, 10 µL of PIC mix was added, which contained ~5-100 nM of each GTF (TFIIA, 
TFIIB, TFIID, TFIIE, TFIIF, TFIIH, RNAPII, and Mediator) with added DB(100) buffer (10% glycerol, 
10 mM Tris pH 7.9, 180 mM KCl, 1 mM DTT). This mix was incubated for 15 minutes to allow PIC 
assembly. Transcription was initiated by addition of A/G/UTP (to 350 µM) and 32P-CTP (400 nM) in 
DB(100) buffer. Reactions were chased one-minute post-initiation by addition of cold CTP to bring 
[CTP] to 350 µM. In some cases, [ATP] was increased to 2 mM.  This protocol ensured predominantly 
single-round transcription based upon 1) the short time-frame of the assay, and 2) chase with cold 
CTP ensures that any potential re-initiation would have 32P-signal reduced by orders of magnitude 
from the initial 32P-CTP pulse.  Single-round transcription was confirmed based upon quantitation of 
total 32P signal (i.e. encompassing all detected transcripts ~20 to 216 nt in length) over time and 
further verified using experiments with added sarcosyl (0.2%), which prevents re-initiation (Hawley 
and Roeder, 1985; Hawley and Roeder, 1987).  Transcription was stopped by addition of 150 µL of 
stop buffer (20 mM EDTA, 200 mM NaCl, 1% SDS). RNA was then ethanol precipitated, washed with 
75% cold ethanol, resuspended in formamide loading buffer, boiled, and loaded onto an acrylamide 
sequencing gel (typically 18%) for analysis.  
For pause index (PI) calculations, 32P-signal was quantitated (with background correction; 
using “subtract background” feature in ImageJ, using a 1000-pixel rolling ball radius across the entire 
gel) from sequencing gels using ImageJ; the ratio of paused (20-80nt) vs. elongated (100-216nt) 
transcripts was reported as the PI.  For each PI plot (Figure 1D or Figure 2F), the data were taken 
from a set of experiments that used the same PIC factors (i.e. TFIIA, TFIIB, TFIID, TFIIE, TFIIF, 
TFIIH, RNAPII, and Mediator from the same preparation).  Because the scale of some PIC factor 
purifications could not accommodate all experiments included in this study, some experiments used 
PIC factors from different preparations at different titrations (determined empirically).  PI data for 
Figure 1D vs. Figure 2F used different preparations of some PIC factors, and this likely contributes to 
the different PI for TFIID-containing PICs.  For any given experiment, regardless of the specific PIC 
factor preparation or titration, NELF/DSIF increased PI (more pausing) and P-TEFb decreased PI 
(less pausing, more pause release). 
 
Primer Extension. Transcription assays were carried out as described above up until the point of 
PIC assembly. To initiate transcription, a final concentration of 400 µM A/G/C/UTP was added, and 
reactions were allowed to proceed for 30 minutes then stopped with 150 µL stop buffer. RNA was 
then phenol:chloroform extracted and ethanol precipitated. Primer extension was carried out using 
AMV reverse transcriptase (RT) as described (https://www.promega.com/products/pcr/rt-pcr/amv-
reverse-transcriptase/?catNum=M5101). The first ~80 nt of the HSPA1B transcript is GC-rich and 
predicted to adopt secondary structures, which can block RT extension.  Thus, extension assays 
were carried out at elevated temperatures that could be tolerated by AMV RT. 
 
Purification of human PIC factors.  Factors were purified as described: TFIIA, TFIIB, TFIID, TFIIE, 
TFIIF, RNAPII, Mediator (Knuesel et al., 2009); TFIIH (Ebmeier et al., 2017).  Briefly, TFIIA, TFIIB, 
TFIIE, and TFIIF were expressed in E. coli and purified over several ion exchange and affinity 
columns.  For RNAPII, nuclear extract from approximately 20 L of HeLa cells was used to start.  After 
the ammonium sulfate (AS) cut, protein was resuspended in 20 mM AS buffer (20 mM HEPES, pH 
7.6; 20% glycerol, 0.2 mM EDTA, 2 mM MgCl2) to a concentration of ca. 10 mg/mL and loaded onto 
an anti-Rpb1 column.  Following incubation, the resin was washed with 50 column volumes 0.5M AS 
buffer B (50 mM Tris, pH 7.9; 10% glycerol, 1 mM EDTA, 10 µM ZnCl2, 0.025% NP-40) and 10 
column volumes 0.1M AS buffer B.  After elution with CTD peptide (4 repeats; 1 mg/mL in 0.1M AS 
buffer B), the sample was loaded onto a UNO-Q column (BioRad) in 0.1M buffer B and eluted with a 
linear gradient of 0.1-0.5M AS.  Pol II eluted at approximately 0.3M AS.  For TFIIH, purification started 
with nuclei from approximately 200L of HeLa cells.  The P1M/Q0.4M fraction was loaded onto an anti-
ERCC3 monoclonal antibody column.  After binding, the column was washed extensively with 0.5M 
KCl HEGN (20 mM HEPES, pH 7.9; 0.1 mM EDTA, 10% glycerol, 0.1% NP-40) followed by elution 
with 1 mg/mL peptide in 0.2M HEGN. TFIID purification typically started with nuclei from 
approximately 200 L HeLa cells.  The P1M/Q0.4M fraction (ca. 2 mg/mL) or the P1M/Q1M fraction 
was loaded onto an anti-TAF4 resin and washed with 40 column volumes 0.7M KCl TGEM (10 mM 
Tris, pH 7.9; 20% glycerol, 0.2 mM EDTA, 4 mM MgCl2) followed by 20 column volumes 0.2M KCl 
TGEM.  TFIID was then eluted from the resin with 1 mg/mL peptide in 0.2M KCl TGEM.  A typical 
Mediator purification started with nuclei from 100L HeLa cells.  The P1M/Q1M fraction is enriched in 
core Mediator (little/no detectable CDK8).  GST-immobilized activation domains of VP16 (aa 413-490) 
or SREBP-1a (aa 1-50) were used.  After binding, the resin was washed with 50 column volumes 
0.5M KCl HEGN (0.1% NP-40), followed by 10 column volumes 0.15M KCl HEGN.  Elution with buffer 
containing 30 mM glutathione (pH 7.6, 20 mM Tris, 0.1 mM EDTA, 10% glycerol, 0.15M KCl) was 
followed by separation over a 15-40% glycerol gradient in 0.15M KCl HEGN with centrifugation at 
50K RPM for 6 h at 4ºC.   
 
Purification of DSIF, NELF, HSF1, and P-TEFb.  The two subunit DSIF complex (SPT4 and SPT5) 
was expressed in Rosetta2(DE3)pLysS cell (Novagen #71403). The expression plasmid was a gift 
from Dr. Rob Fisher. The four subunit NELF complex (NELF A, B, C, and E) was expressed in 
Rosetta2(DE3)pLysS (Novagen #71403) cells. The expression plasmids were a gift from Dr. W. Lee 
Kraus.  The two subunit P-TEFb complex (CDK9 and CCNT1) was expressed in Sf9 cells at the UC 
Tissue Culture Shared Resource.  For each of these complexes, the cell lysate was treated with 
benzonase, clarified, and loaded onto a Ni-NTA agarose column (Invitrogen #R90101). The column 
was then extensively washed with 0.5M NaCl buffer (pH 7.5; 50mM Tris, 5mM b-mercatoethanol, 
10mM imidazole) and eluted in 0.15M KCl buffer (pH 7.5; 20mM Tris, 1mM b-mercaptoethanol, 0.5M 
imidazole).  HSF1 was expressed in BL21(DE3) cells (Novagen #69450). The lysate from bacterial 
expression was clarified and purified in batch over a Ni-NTA agarose resin and washed and eluted as 
described above. 
 
Recombinant expression and purification of holo-TFIID and partial TAF complexes.  All TAFs 
and TFIID complexes, including holo-TFIID, were expressed using the MultiBac baculovirus system 
following published protocols (Fitzgerald et al., 2006). All proteins were full-length unless indicated 
otherwise. 
For the recombinant human TAF1,7,11,13,TBP (S-TAF) complex, TAF1 comprising an N-
terminal maltose binding protein (MBP) tag with a tobacco etch virus (TEV) NIa proteolytic cleavage 
site, TAF7 comprising an N-terminal hexa-histidine tag with a TEV NIa site, TAF11, TAF13 and TBP 
core (AA155-335) were used. Insect cell pellets comprising the S-TAF complex were resuspended in 
IMAC Buffer A (1x PBS pH 7.5, 400mM NaCl, 50mM imidazole, 10mM MgCl2, 5% glycerol (w/v), 
complete protease inhibitor). Cells were lysed by freeze-thawing (twice), followed by centrifugation at 
45,000xg for 60 min to clear the lysate. Cleared lysate was then applied to Ni-NTA resin, pre-
equilibrated with IMAC Buffer A, followed by washing (10 column volumes) with IMAC Buffer A, then 
IMAC Buffer HS (1x PBS pH 7.5, 1000mM NaCl, 50mM imidazole, 10mM MgCl2, 5% glycerol (w/v), 
complete protease inhibitor (Roche Molecular Biochemicals)) and then again with IMAC Buffer A. 
Bound S-TAF complex was eluted using IMAC buffer B (1x PBS pH 7.5, 400mM NaCl, 500mM 
imidazole, 10mM MgCl2, 5% glycerol (w/v), complete protease inhibitor). Fractions containing the S-
TAF complex were dialyzed overnight against MonoQ Buffer A (1x PBS pH 7.5, 100mM NaCl, 10mM 
MgCl2, 5mM β-mercaptoethanol with complete protease inhibitor). S-TAF was further purified using 
ion exchange chromatography with a MonoQ column pre-equilibrated with MonoQ Buffer A. After 
binding, column was washed (5 column volumes) with MonoQ Buffer A and S-TAF eluted using a 
continuous gradient to MonoQ Buffer B (1x PBS pH 7.5, 1 M NaCl, 10mM MgCl2, 5mM β-
mercaptoethanol, complete protease inhibitor (Roche Molecular Biochemicals)) from 0-100% linear 
gradient. The complex was further purified by size exclusion chromatography (SEC) with a Sephacryl 
S400 16/60 column in SEC Buffer 2 (25mM HEPES pH 7.5, 300mM NaCl, 10mM MgCl2, 5mM β-
mercaptoethanol, complete protease inhibitor).  The human TAF3/TAF10 complex was purified from 
insect cell pellets using the same protocol that was used for the S-TAF complex.  Both TAF3 and 
TAF10 possess a C-terminal hexa-histidine tag.  
Recombinant human holo-TFIID was reconstituted in vitro from purified 8TAF, S-TAF and the 
TAF3/TAF10 complex in SEC Buffer 2 (25mM HEPES pH 7.5, 300mM NaCl, 10mM MgCl2, 5mM β-
mercaptoethanol, complete protease inhibitor) and purified by SEC in SEC Buffer 2. Recombinant 
human TFIID eluted in a symmetric peak. Peak fractions were pooled, concentrated to 0.6 mg/ml and 
holo-TFIID stored frozen in SEC Buffer 2 supplemented with 10% glycerol. 
 
Statistical analysis of in vitro data 
Statistical comparison of in-vitro data was performed using a Welch's t-test, to determine a p-value 
while accounting for variance in sample sizes. In the case where fold-change data was compared, the 
data was first log transformed and an Anderson-Darling test was used to ensure that the data was not 
significantly different from normal (p < 0.05). A one-sided t-test was then used to calculate a p-value 
for the data relative to 0, which is the log-transformed value of a 1-fold change. 
 
Calculation of Differential Motif Displacement Scores 
Differential Motif Displacement scores were calculated as described (Tripodi et al., 2018), using the 
implementation provided by the Transcription Factor Enrichment Analysis program 
(https://github.com/Dowell-Lab/TFEA). The HOCOMOCO core database version 11 was used to 
indicate motifs of interest. 
 
Analysis of Pause Index variability in cells, replicate-to-replicate  
Variability in PI between biological replicates was determined by comparing the calculated PI 
between the replicates, as a fold change. PI was calculated as described (Ebmeier et al., 2017). 
Comparisons at the HSPA1B gene were used to match the in vitro promoter.  PRO-seq data from this 
study (HCT116 cells) yielded inter-sample variability of 2.0 in control cells, and 2.7 in TAF1/2-
depleted cells (fold change).  For comparison, we also performed a similar analysis on the 12.5 
minute heat shock time-point a different PRO-seq study (Mahat et al., 2016).  In agreement, these 
data gave an inter-sample PI variability of 2.0 (fold change).  This level of variability is consistent with 
that observed, replicate-to-replicate, in our in vitro reconstituted transcription system (Fig. 1D).    
 
Purification of recombinant TAF1 antibody. The antibody was purchased from the Recombinant 
Antibody Network (RAN; https://recombinant-antibodies.org); several TAF1 antibodies were tested 
and we determined that anti-TAF1-RAB-C413 performed best in TFIID IP experiments from nuclear 
extracts. Anti-TAF1 expression plasmids were transformed into OverExpress C43(DE3) chemically 
competent cells and expressed according to standard protocols. Protein was then isolated via batch 
purification over Protein A beads according to the Recombinant Antibody Network (RAN) protocol. 
For the IP tests, 1mL of anti-TAF1 C413 antibody lysate was added to 100 µl of washed and 
equilibrated protein A beads. The tube was nutated at 4˚C for 1 hour and centrifuged at 400xg to 
removed unbound material. The resin was then washed 3 times in 0.5M HEGN and 3 times in 0.15M 
HEGN buffer. The anti-TAF1 resin was then incubated with 1mL of HCT116 nuclear extract and 
nutated at 4˚C for 2 hours. The tube was centrifuged at 400xg, and the flow through was removed. 
The resin was then washed three times in 0.5M HEGN and three times in 0.15M HEGN buffer. 
Elutions were performed with 2% sarkosyl in 0.15M HEGN solution (2 x 100 µl at 4˚C for 30 minutes). 
A negative control consisted of HCT116 nuclear extract added to Protein A beads without antibody.  
 
TRIM-Away.  The method used was adapted from Clift et al. (Clift et al., 2017).  HCT116 cells 
cultured in McCoy’s 5A medium were grown to approximately 70% confluency. Media was aspirated 
off, and the cells were washed with PBS. 2ml of trypsin per plate were used to harvest adherent cells, 
after which an equal volume of Opti-MEM was added to each plate to neutralize the trypsin. Cells 
were combined in a 50ml centrifuge tube and spun down at 2,000xg for 5 minutes, then washed in 
PBS and spun down again at 2,000xg for 5 minutes. Cells were counted using a hemocytometer and 
diluted to 25 million cells/mL. 100 µl reactions were prepared, and cells were re-suspended in Buffer 
R and anti-TAF1 C413 antibody. A pulse only control was prepared, which consisted of cells 
suspended only in Buffer R. Transfections were performed using the Neon Transfection Kit (1530V, 
1ms width, 1 pulse). Transfected cells were then pipetted into 1 mL of Opti-MEM in a 35mm dish and 
incubated at 37˚C for 1 hour. The Opti-Mem media (containing some suspended cells) was then 
pipetted off and saved. 500 µl of PBS was added to the cells on the plates, which were then 
harvested and centrifuged at 6,000xg for 5 minutes. Supernatant was aspirated off, and cell nuclei 
were subsequently isolated. A small sample of cells (50 µl) were saved for analysis via western blot. 
 
Quantitation of TFIID subunits. Whole cell extracts or nuclei + cytoplasm were isolated following 
either pulse-only control or TAF1/2 Trim-Away knockdown as described above. Nuclei were re-
suspended in RIPA buffer with protease inhibitors, biorupted, and treated with nucleases.  Protein 
concentrations of each fraction was determined and 10µg total protein was loaded onto 4-20% 
gradient protein gels (BioRad 4–20% Mini-PROTEAN® TGX™ Gel, 15 well, 15 µl cat#456-1096) and 
transferred onto a nitrocellulose membrane for western blotting.  Westerns were scanned on an 
ImageQuant LAS 4000 series imager.  ImageJ software was then used to measure band intensity, 
which was normalized to Actinβ for quantitation. 
 
Antibodies. For western blotting, the following antibodies were used: TAF1 (1:1000, sc-735 X, Santa 
Cruz Biotechnology), TAF2 (1:500, ab103468, abcam), TAF4 (1:250, 07-1803, Millipore Sigma), 
TAF8 (1:250, ab204894, abcam), TBP (1:2000, sc-273, Santa Cruz Biotechnology), actin (1:1000, sc-
47778, Santa Cruz Biotechnology), and histone H3 was a rabbit polyclonal from A. Shilatifard 
(Ebmeier et al., 2017). TAF1 Trim-Away was completed with the TAF1 C413 antibody from the 
Recombinant Antibody Network (RAN; https://recombinant-antibodies.org). Antibodies against 
Drosophila proteins were monoclonals 30H9 (Taf1) (Weinzierl et al., 1993) and 3E12 (Taf4) (Marr et 
al., 2006). 
  
Drosophila RNAi and S2 nuclei isolation. RNAi was performed as described (Clemens et al., 2000) 
using 20-40 µg dsRNA. Cells were incubated with dsRNA for 2.5 d.  Following RNAi with either TAF1 
dsRNA or a LacI dsRNA control, cells were processed using the nuclei isolation steps as described 
(Mahat et al., 2016) before flash-freezing and storing at -80ºC. 
  
Measuring TAF1 knockdown from S2 cells. Following RNAi treatment samples were run on a 
SurePAGE Bis-Tris 4-12% gel (GenScript) at 200V for 70 min. Protein was then transferred onto a 
nitrocellulose membrane (80V for 2hrs).  For imaging and quantitation, membranes were exposed for 
sub-saturated times (BIO-RAD Chemidoc MP). 
 
Sequencing data processing. The initial processing of all sequencing data was performed using the 
NascentFlow Pipeline (doi: 10.17605/OSF.IO/NDHJ2), a data processing pipeline written in the 
Groovy programming language. The code for this pipeline can be found at https://github.com/Dowell-
Lab/Nascent-Flow, with analysis for this experiment performed at commit 3fe1b7. Data were mapped 
to the hg38 reference genome for human cells, and to the dm6 reference genome for Drosophila S2 
cells. For the remainder of the analysis, only the maximally expressed isoform of each gene was 
considered, which was determined by calculating the RPKM normalized expression over each 
isoform and selecting the one with the maximum RPKM expression. When different isoforms were 
determined across samples, the isoform from the first control sample was selected. In HCT116 cells, 
this was sample PO_1_S1_R1_001 whereas in S2 cells this was sample Control_1_S1_R1_001. 
 
PRO-seq normalization with nuclear run-on.  To test whether TAF1/2 knockdown caused a 
significant change in global gene expression, we directly compared run-on transcription levels in 
control and knockdown samples.  A 50 μl aliquot (CTRL or TAF1/2-knockdown) containing 1 million 
nuclei was divided into 2 x 25 µL; one 25 µL aliquot was heated to 95ºC for 5 minutes and the other 
was kept on ice. Then 25 µL of Reaction Buffer (5 mM Tris pH 8.0, 5 mM MgCl2, 0.5 mM DTT, 150 
mM KCl, 5 units of SUPERase-In, 0.5% Sarkosyl, 125 µM ATP, GTP, UTP, 2 µM CTP and 2.5µL a-
32P CTP) and incubated for 3 min at 37°C.  RNA was isolated with 500µL of Trizol LS, followed by 
addition of 130 μl chloroform.  Samples were then centrifuged for 10 min and the aqueous phase was 
transferred to a new tube.  RNA was precipitated by adding 1 μl glyco-blue and 2.5 volumes 100% 
ethanol to each sample. Samples were incubated at room temperature for 10 minutes, then 
centrifuged for 20 minutes. Sample pellet was resuspended in 50 µL DEPC water. Buffer exchange 
was completed with a P-30 column according to the manufacturer’s instructions (BioRad cat # 732-
6250). Scintillation counts were measured by diluting 1 µL of sample in 1 mL of scintillation fluid.  
 
Normalization using PRO-seq reads at 3’-ends of long genes.  As another normalization method 
for PRO-seq libraries, we implemented a previously published approach (Mahat et al., 2016) that 
compares PRO-seq reads at the 3’-end of very long genes.  The key assumption of this 
computational method is that genes exhibiting baseline levels of transcription will be unaffected by 
perturbations if they are long enough and the perturbation is short enough that its effects have not 
propagated through the entire gene body. Because Trim-Away was implemented for only 60 minutes, 
genes long enough to include in this analysis were calculated using polymerase elongation rate and 
treatment time (2kb/min * 60 min = 120kb) with an added 500bp to exclude the 3’ region, which often 
contains read pileup (final length cutoff=120.5kb, n=2,139).  From this gene set, we determined the 
raw read counts within the region 120kb to -0.5kb from the TES and averaged this count between 
replicates. We then performed a linear regression on the count values for each of these genes 
(control and TAF1/2 knockdown). The results indicated that the baseline transcription between control 
and TAF1/2 knockdown cells was not significantly altered. 
 
PRO-seq 
Nuclei Preparation: After treatment, HCT116 cells (control or TAF1 TRIM-Away) were washed 3x with 
ice cold PBS, and then treated with 10 ml (per 15 cm plate) ice-cold lysis buffer (10 mM Tris–HCl pH 
7.4, 2 mM MgCl2, 3 mM CaCl2, 0.5% NP-40, 10% glycerol, 1 mM DTT, 1x Protease Inhibitors (1mM 
Benzamidine (Sigma B6506-100G), 1mM Sodium Metabisulfite (Sigma 255556-100G), 0.25mM 
Phenylmethylsulfonyl Fluoride (American Bioanalytical AB01620), and 4U/mL SUPERase-In). Cells 
were centrifuged with a fixed-angle rotor at 1000×g for 15 min at 4°C. Supernatant was removed and 
pellet was resuspended in 1.5 mL lysis buffer to a homogenous mixture by pipetting 20-30X before 
adding another 8.5 mL lysis buffer. Suspension was centrifuged with a fixed-angle rotor at 1000×g for 
15 min at 4°C. Supernatant was removed and pellet was resuspended in 1 mL of lysis buffer and 
transferred to a 1.7 mL pre-lubricated tube (Costar cat. No. 3207). Suspensions were then pelleted in 
a microcentrifuge at 1000×g for 5 min at 4°C. Next, supernatant was removed and pellets were 
resuspended in 500 μL of freezing buffer (50 mM Tris pH 8.3, 40% glycerol, 5 mM MgCl2, 0.1 mM 
EDTA, 4U/ml SUPERase-In). Nuclei were centrifuged 2000×g for 2 min at 4°C. Pellets were 
resuspended in 100 μL freezing buffer. To determine concentration, nuclei were counted from 1 μL of 
suspension and freezing buffer was added to generate 100 μL aliquots of 10 × 106 nuclei. Aliquots 
were flash frozen in liquid nitrogen and stored at −80°C.  
Nuclear run-on and RNA preparation: Nuclear run-on experiments (HCT116 and S2 cells) were 
performed as described (Mahat et al., 2016) with the following modifications: the final concentration of 
non-biotinylated CTP was raised from 0.25 µM to 25 µM, and the final library clean-up and size 
selection was accomplished using 1X AMPure XP beads (Beckman).  
Sequencing: Sequencing of PRO-seq libraries was performed at the BioFrontiers Sequencing Facility 
(UC-Boulder). Single-end fragment libraries (75 bp) were sequenced on the Illumina NextSeq 500 
platform (RTA version: 2.4.11, Instrument ID: NB501447), demultiplexed and converted BCL to fastq 
format using bcl2fastq (bcl2fastq v2.20.0.422); sequencing data quality was assessed using FASTQC 
(v0.11.5) (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and FastQ Screen (v0.11.0, 
https://www.bioinformatics.babraham.ac.uk/projects/fastq_screen/). Trimming and filtering of low-
quality reads was performed using BBDUK from BBTools (v37.99) and FASTQ-MCF from EAUtils 
(v1.05). Alignment to the human reference genome (GRCh37/hg38) was carried out using Hisat2 
(v2.1.0) (Kim et al., 2015) in unpaired, no-spliced-alignment mode with a GRCh37/hg38 index, and 
alignments were sorted and filtered for mapping quality (MAPQ>10) using Samtools (v1.5) (Li et al., 
2015). Gene-level count data for transcription start site (TSS, -30 to +300) and gene body (+301 to 
end) regions were obtained using featureCounts from the Subread package (v1.6.2) (Liao et al., 
2013) with custom annotation files for single unique TSS and gene body regions per gene. Custom 
annotation files with single unique TSS and gene body regions per gene were generated as follows: 
1) hg38 RefSeqCurated transcript-level annotation was downloaded from the UCSC genome table 
browser (09-07-2018), transcripts shorter than 1500bp and non-standard chromosome were 
removed, and only transcripts with unique start/stop coordinates per gene were retained; 2) Sense 
and anti-sense counts were tabulated and each candidate TSS region was ranked by sense and 
antisense reads to obtain a single ‘most-active’ TSS per gene; 3) Finally, per gene, the TSS was 
combined with the shortest gene body to avoid the influence of alternative transcription 
termination/polyadenylation sites. Differential expression analysis of gene body regions was 
assessed using the DESeq2 package (v1.22.1) (Love et al., 2014) with a custom R script (R v3.5.1 / 
RStudio v1.1.453 / Bioconductor v3.7) with cutoffs as described in text and figure legends. Analysis of 
RNAPII pausing was carried out using a custom R script (R v3.5.1 / RStudio v1.1.453) with the 
ggplot2 package (v3.1.0) used for visualizations. Gene level TSS and gene body counts were 
normalized by counts-per-million and by region length (cpm/bp), and Pausing Index (PI) calculated as 
the ratio of normalized reads in the TSS (cpm/bp) to normalized reads in the gene body (cpm/bp). 
Genes with <0.5 cpm in all samples were excluded from analysis. Means of replicate values were 
used for plots and Wilcoxon/Mann-Whitney U tests. For genome browser snapshots, aligned reads 
were downsampled to the lower aligned read count per replicate using Samtools, to ensure equal 
contributions from each replicate, followed by merging of replicates and generation of coverage tracks 
in the bedgraph format using HOMER (v4.9.1) (Heinz et al., 2010). Genome browser snapshots were 
then generated from the bedgraph files using a custom R script (R v3.5.1 / RStudio v1.1.453 / 
Bioconductor v3.7) and the Gviz package (v1.26.4) (Hahne and Ivanek, 2016). 
 
Metagene analysis.  Each gene in the isoform-resolved reference sequence was either collapsed 
into a fixed sequence length originating from the TSS or TES (to better aggregate information, 
restricted to small regions) or divided into a fixed number of bins of variable length (to be used to 
accommodate genes of different length, but has some biases arising from length differences). The 
utility featurecounts (Liao et al., 2013) was then used to determine the total counts in those regions 
and the mean count and standard deviation of the mean were calculated. All counts over base pairs 
or bins were then plotted along with the standard deviation. 
 
5’-end/3’-end gene ratio histogram.  Long genes used for 3’-end normalization (n=2139) were 
divided in half and reads were counted in each half (5’-end or 3’-end). For each gene, a ratio of 2nd 
half (3’-end) and 1st half (5’-end) reads was calculated. These results were plotted as a histogram for 
control cells and TAF1/2 Trim-Away cells. 
 
Principal Component Analysis. PCA was performed using the standard prcomp function provided 
by the sva package for the R programming language (Leek et al., 2019). Batch effects from replicates 
completed on different days replicates were corrected using the removeBatchEffect function provided 
by the limma package (Ritchie et al., 2015) from the R programming language. 
 
Differential Expression analysis. Differential expression analysis was performed using the DESeq2 
package (Love et al., 2014) for the R programming language. Counts were generated using the utility 
featurecounts. Initial analysis using counts across the full annotated gene showed significant skew, 
indicating that the baseline assumptions of the differential expression model did not hold. To correct, 
counts in the region from +500 of the TSS to -500 from the TES (Transcription End Site) were used to 
obtain suitable model weights. Those model weights were then used when performing differential 
expression across the full gene, which corrected the skew effect. 
 
Gene Set Enrichment Analysis. GSEA (Subramanian et al., 2005) was performed with the Broad 
Institute’s GSEA software on the GenePattern Server using the pre-ranked module. Log(2) fold-
change values were used as the rank metric for all genes and compared against the Hallmark gene 
sets database for enrichment. 
 
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
PRO-seq experiments were completed in biological replicate.  Statistical analysis of PRO-seq data is 
described in the Method Details.  The number of replicates for each in vitro transcription experiment is 
indicated in the Figure Legends.  Statistical analysis of in vitro transcription data is provided in Figure 
Legends and Method Details. 
 
DATA AND CODE AVAILABILITY 
PRO-Seq data (HCT116 and S2 cells) have been uploaded on GEO: GSE132764.  Information about 
how to access the NascentFlow data processing pipeline is provided here (doi: 
10.17605/OSF.IO/NDHJ2).  All code used in this analysis as well as additional documentation can be 
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Fig.1 | Biochemical reconstitution of promoter-proximal pol II pausing with purified human 
factors. a, Schematic of HSPA1B promoter and workflow of in vitro transcription assay. b, 
Representative data from in vitro transcription reactions with the complete PIC (TFIIA, IIB, IID, IIE, IIF, 
IIH, Mediator, pol II; lane 2) or supplemented with NELF/DSIF (lane 3) and P-TEFb (lane 4).  A “no 
pol II” control experiment is shown in lane 1. At left are approximate lengths (in bases) of the RNA 
transcripts, with paused and elongated transcript regions highlighted in orange or green, respectively. 
Note greater numbers of transcripts in paused region coupled with reduced transcripts in elongation 
region upon addition of NELF and DSIF (lane 2 vs. lane 3); addition of P-TEFb reverses this trend 
(lane 3 vs. lane 4). c, A time course showing maximum paused transcripts at 5 minutes and 
maximum elongated transcripts at 10 minutes; an increase in elongated transcripts correlates with 
decreased paused transcripts (5 min vs. 10 min), suggesting paused complexes ultimately generate 
elongated products. d, Calculation of an in vitro pause index (PI) at the HSPA1B promoter, using 
paused and elongated regions defined in b (n = 8). As expected, PI increased upon addition of NELF 














Fig.2 | TFIID is required to establish pol II promoter-proximal pausing in vitro. a, Reconstituted 
transcription reactions with PICs containing TFIID or TBP (i.e. reactions contain TFIIA, IIB, IIE, IIF, 
IIH, Mediator, and pol II, plus either TFIID or TBP).  Note that PICs with TBP still support elongated 
transcription, but paused products are absent. b, Coomassie-stained gel of the complete human 
TFIID complex, generated by recombinant expression. c, As with endogenously purified human 
TFIID, PICs with recombinant TFIID support transcription and pol II promoter-proximal pausing. Note 
that elongated products are obscured in rTFIID lane because of a cracked gel. d, Schematic of 
human TFIID structure bound to promoter DNA [Patel/Nogales 2018; Louder/Nogales 2016]. e, 
coomassie-stained gels of partial TFIID complexes lacking TAF1 and TAF2 (7-TAF) or containing 
TAF2 (8-TAF) or TAF1 (S-TAF). f, Plot of PI comparing in vitro transcription experiments with PICs 
containing partial TAF complexes. Note that PI increases in presence of TAF1 or TAF2; because 7-

















Fig. 3 | Loss of TAF1 and/or TAF2 disrupts transcription in human and Drosophila cells, 
especially at promoter-proximal pause regions. a, Workflow for TRIM-Away[Clift/Schuh Cell 2017] 
and PRO-Seq [Kwak/Lis Science 2013]. b, Representative western blots and quantitation (at right) for 
TFIID subunits.  Bar plots represent mean and standard error, with actin as a loading control. c, MA 
plot showing a genome-wide up-regulation of transcription in TAF1 TRIM-Away cells compared with 
controls.  As shown in the metagene plots (d), much of this increased transcription was localized to 
gene 5’-ends, which coincides with the pol II pause region. Metagene generated from top 500 
expressed genes. Similar results were observed in TAF1 knockdown Drosophila S2 cells vs. controls 
(inset; n = XXXX). 
 
Fig. 4 | Pol II promoter-proximal pausing is disrupted genome-wide upon TAF knockdown in 
human or Drosophila cells. a, Example PRO-Seq data from HCT116 cells (IGV traces). b, TAF 
knockdown increases PI in human (HCT116) and c, Drosophila (S2) cells.  Cumulative distribution 
plots of PI are shown for all “expressed” genes (HCT116; n=5303) as defined [Ebmeier 2017] and all 
“paused” genes (S2 cells; n=3225), as defined by Kwak et al. [Science 2013 950]. d, Model. TFIID is 
required to establish pol II promoter-proximal pausing; disruption of TFIID correlates with increased 
pol II release from promoter-proximal pause regions.  Release of paused pol II, in turn, enables 
additional pol II complexes to re-initiate transcription [Cramer/Eick eLife 2017; Shao/Zeitlinger Nat 
Genet 2018].  Collectively, this generates increased reads around the pause region (i.e. toward gene 
5’-ends).  Pol II pausing may be especially dependent on TFIID lobe C subunits TAF1 and TAF2 
because they bind Inr and downstream promoter elements; however, the precise molecular 
mechanism remains incomplete. Interestingly, although pause release and increased 5’-end reads 
were evident at thousands of genes in HCT116 cells, most gene transcript reads abruptly decreased 
after a few hundred bases (e.g. +300), suggesting additional regulatory mechanisms downstream of 
the pause site. 
 
